US FDA Authorized AffaMed’s Bispecific Biologic for Treating Retinal Vascular Diseases
The company ‘AffaMed Therapeutics’, a clinical stage biotechnology company that is dedicated to the commercialization and development of the transformative pharmaceutical, surgical and digital products announced that, the Food and Drug Administration (FDA) of the United States has now cleared the application of the Investigational New Drug (IND) for the clinical development of the AM712, […]
Continue Reading